US 12,168,666 B2
Morphic forms of trilaciclib and methods of manufacture thereof
Stephen Schneider, Raleigh, NC (US); Alexander Smith, Apex, NC (US); Hannah S. White, Chapel Hill, NC (US); Jay Copeland Strum, Hillsborough, NC (US); and Jaroslaw Mazurek, Amsterdam (NL)
Assigned to G1 Therapeutics, Inc., Research Triangle Park, NC (US)
Filed by G1 Therapeutics, Inc., Research Triangle Park, NC (US)
Filed on Apr. 21, 2021, as Appl. No. 17/236,687.
Application 17/236,687 is a continuation of application No. 17/097,854, filed on Nov. 13, 2020, granted, now 10,988,479.
Claims priority of provisional application 63/039,372, filed on Jun. 15, 2020.
Prior Publication US 2021/0387993 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/20 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01)
CPC C07D 487/20 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); C07B 2200/13 (2013.01)] 27 Claims
OG exemplary drawing
 
1. A crystalline compound of structure:

OG Complex Work Unit Chemistry
which is a dihydrochloride.